{"id":19175,"date":"2024-06-19T18:36:17","date_gmt":"2024-06-19T21:36:17","guid":{"rendered":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/pionera-cancer-de-mama-re-her2-avancado-ou-metastatico\/"},"modified":"2026-04-24T15:38:55","modified_gmt":"2026-04-24T18:38:55","slug":"pionera-cancer-de-mama-re-her2-avancado-ou-metastatico","status":"publish","type":"ensaio_clinico","link":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/pionera-cancer-de-mama-re-her2-avancado-ou-metastatico\/","title":{"rendered":"PionERA \u2013 C\u00e2ncer de mama RE+, HER2-, avan\u00e7ado ou metast\u00e1tico"},"content":{"rendered":"<div>Avaliar a efic\u00e1cia e a seguran\u00e7a de Giredestranto em compara\u00e7\u00e3o com Fulvestranto, ambos combinados com um inibidor de CDK4\/6.<\/div>\n<div><\/div>\n<div>Clinical Trials: NCT06065748<\/div>\n<div aria-hidden=\"true\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Avaliar a efic\u00e1cia e a seguran\u00e7a de Giredestranto em compara\u00e7\u00e3o com Fulvestranto, ambos combinados com um inibidor de CDK4\/6. Clinical Trials: NCT06065748<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false},"class_list":["post-19175","ensaio_clinico","type-ensaio_clinico","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PionERA \u2013 C\u00e2ncer de mama RE+, HER2-, avan\u00e7ado ou metast\u00e1tico - IDOR - Instituto D&#039;Or de Pesquisa e Ensino<\/title>\n<link rel=\"canonical\" href=\"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/pionera-cancer-de-mama-re-her2-avancado-ou-metastatico\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PionERA \u2013 C\u00e2ncer de mama RE+, HER2-, avan\u00e7ado ou metast\u00e1tico - IDOR - Instituto D&#039;Or de Pesquisa e Ensino\" \/>\n<meta property=\"og:description\" content=\"Avaliar a efic\u00e1cia e a seguran\u00e7a de Giredestranto em compara\u00e7\u00e3o com Fulvestranto, ambos combinados com um inibidor de CDK4\/6. Clinical Trials: NCT06065748\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/pionera-cancer-de-mama-re-her2-avancado-ou-metastatico\/\" \/>\n<meta property=\"og:site_name\" content=\"IDOR - Instituto D&#039;Or de Pesquisa e Ensino\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-24T18:38:55+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/pionera-cancer-de-mama-re-her2-avancado-ou-metastatico\\\/\",\"url\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/pionera-cancer-de-mama-re-her2-avancado-ou-metastatico\\\/\",\"name\":\"PionERA \u2013 C\u00e2ncer de mama RE+, HER2-, avan\u00e7ado ou metast\u00e1tico - IDOR - Instituto D&#039;Or de Pesquisa e Ensino\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/#website\"},\"datePublished\":\"2024-06-19T21:36:17+00:00\",\"dateModified\":\"2026-04-24T18:38:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/pionera-cancer-de-mama-re-her2-avancado-ou-metastatico\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/pionera-cancer-de-mama-re-her2-avancado-ou-metastatico\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/pionera-cancer-de-mama-re-her2-avancado-ou-metastatico\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/ptbr.idor.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ensaios Cl\u00ednicos\",\"item\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"PionERA \u2013 C\u00e2ncer de mama RE+, HER2-, avan\u00e7ado ou metast\u00e1tico\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/#website\",\"url\":\"https:\\\/\\\/ptbr.idor.org\\\/\",\"name\":\"IDOR - Instituto D&#039;Or de Pesquisa e Ensino\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ptbr.idor.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PionERA \u2013 C\u00e2ncer de mama RE+, HER2-, avan\u00e7ado ou metast\u00e1tico - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","canonical":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/pionera-cancer-de-mama-re-her2-avancado-ou-metastatico\/","og_locale":"pt_BR","og_type":"article","og_title":"PionERA \u2013 C\u00e2ncer de mama RE+, HER2-, avan\u00e7ado ou metast\u00e1tico - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","og_description":"Avaliar a efic\u00e1cia e a seguran\u00e7a de Giredestranto em compara\u00e7\u00e3o com Fulvestranto, ambos combinados com um inibidor de CDK4\/6. Clinical Trials: NCT06065748","og_url":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/pionera-cancer-de-mama-re-her2-avancado-ou-metastatico\/","og_site_name":"IDOR - Instituto D&#039;Or de Pesquisa e Ensino","article_modified_time":"2026-04-24T18:38:55+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. tempo de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/pionera-cancer-de-mama-re-her2-avancado-ou-metastatico\/","url":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/pionera-cancer-de-mama-re-her2-avancado-ou-metastatico\/","name":"PionERA \u2013 C\u00e2ncer de mama RE+, HER2-, avan\u00e7ado ou metast\u00e1tico - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","isPartOf":{"@id":"https:\/\/ptbr.idor.org\/#website"},"datePublished":"2024-06-19T21:36:17+00:00","dateModified":"2026-04-24T18:38:55+00:00","breadcrumb":{"@id":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/pionera-cancer-de-mama-re-her2-avancado-ou-metastatico\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/pionera-cancer-de-mama-re-her2-avancado-ou-metastatico\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/pionera-cancer-de-mama-re-her2-avancado-ou-metastatico\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/ptbr.idor.org\/"},{"@type":"ListItem","position":2,"name":"Ensaios Cl\u00ednicos","item":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/"},{"@type":"ListItem","position":3,"name":"PionERA \u2013 C\u00e2ncer de mama RE+, HER2-, avan\u00e7ado ou metast\u00e1tico"}]},{"@type":"WebSite","@id":"https:\/\/ptbr.idor.org\/#website","url":"https:\/\/ptbr.idor.org\/","name":"IDOR - Instituto D&#039;Or de Pesquisa e Ensino","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ptbr.idor.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"}]}},"_links":{"self":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/ensaio_clinico\/19175","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/ensaio_clinico"}],"about":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/types\/ensaio_clinico"}],"wp:attachment":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/media?parent=19175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}